62.27 +1.01 (1.65%)
After hours: 4:03PM EST
|Bid||61.60 x 800|
|Ask||62.97 x 800|
|Day's Range||59.29 - 62.00|
|52 Week Range||38.05 - 66.30|
|Beta (3Y Monthly)||0.49|
|PE Ratio (TTM)||27.23|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.00|
Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.
Tilray (TLRY) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article we look at what those investors think of BioSpecifics Technologies Corp. (NASDAQ:BSTC). Is BioSpecifics Technologies […]
Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.
Galmed Pharmaceuticals (GLMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
LYNBROOK, N.Y., Nov. 15, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC) a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that Ron Law, Ph.D., J.D. has been appointed as Senior Vice President of Business Development and will be responsible for strategic partnerships, reporting directly to Thomas L. Wegman, President of BioSpecifics. Dr. Law has been consulting for BioSpecifics since July 15, 2018. Dr. Law was most recently the Chief Strategy Officer of Oramed Pharmaceuticals Inc., where he was responsible for the development of execution of scientific and business collaborations and partnerships, as well as the identification of new targets and indications for its platform oral peptide delivery technology and pipeline expansion.
This mutual fund is focused on small-cap stocks, and the fund's managers like the outlook for small caps.
Thomas Wegman became the CEO of BioSpecifics Technologies Corp (NASDAQ:BSTC) in 2007. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
BioSpecifics (BSTC) delivered earnings and revenue surprises of 25.45% and 13.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lynbrook, New York-based company said it had profit of 69 cents. The biopharmaceutical company posted revenue of $8.2 million in the period. BioSpecifics shares have increased ...
- Positive Phase 3 data from both RELEASE-1 and RELEASE-2 trials of CCH for the treatment of cellulite recently reported - - Reported positive topline data from Phase 1 trial of CCH for treatment of uterine ...
On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LYNBROOK, N.Y., Oct. 31, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced positive topline data from its Phase 1 trial of Collagenase Clostridium Histolyticum (CCH) for the treatment of uterine fibroids. Pharmacodynamic changes were noted in all secondary endpoints with the exception of apoptosis. Statistically significant reductions in collagen content were observed as compared to control fibroids with a median reduction of 39 percent (p
Emergent BioSolutions is the IBD Stock Of The Day as the company's shares sidestepped a biotech sell-off. On the stock market today, Emergent Bio stock jumped 3.1% to close at 60.33.
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.